Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its target price boosted by Barclays from $58.00 to $60.00 in a research ...